Japan Recombinant Protein Therapeutics Cdmo Market Size & Outlook
Japan recombinant protein therapeutics cdmo market, 2018-2030 (US$M)
Related Markets
Japan recombinant protein therapeutics cdmo market highlights
- The Japan recombinant protein therapeutics cdmo market generated a revenue of USD 1,393.7 million in 2023 and is expected to reach USD 3,578.9 million by 2030.
- The Japan market is expected to grow at a CAGR of 14.4% from 2024 to 2030.
- In terms of segment, interferons was the largest revenue generating type in 2023.
- Growth Hormones is the most lucrative type segment registering the fastest growth during the forecast period.
Recombinant protein therapeutics cdmo market data book summary
| Market revenue in 2023 | USD 1,393.7 million |
| Market revenue in 2030 | USD 3,578.9 million |
| Growth rate | 14.4% (CAGR from 2023 to 2030) |
| Largest segment | Interferons |
| Fastest growing segment | Growth Hormones |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Growth Hormones, Interferons, Vaccines, Immunostimulating Agents |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, FUJIFILM Holdings Corp, WuXi Biologics (Cayman) Inc, Batavia Biosciences, Richter-Helm, Curia, HALIX, Biovian, Enzene Biosciences |
Other key industry trends
- In terms of revenue, Japan accounted for 6.7% of the global recombinant protein therapeutics cdmo market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan recombinant protein therapeutics cdmo market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 2,968.6 million by 2030.
Interferons was the largest segment with a revenue share of 21.49% in 2023. Horizon Databook has segmented the Japan recombinant protein therapeutics cdmo market based on growth hormones, interferons, vaccines, immunostimulating agents covering the revenue growth of each sub-segment from 2018 to 2030.
This growth can be attributed to numerous factors such as the growing pharmaceutical industry, increasing demand for outsourcing services, and rising R&D activities. In addition, with growing R&D and demand for CDMOs, several drug candidates are in the pipeline.
Furthermore, continuous demand for recombinant protein therapeutics has led to a large number of pharmaceutical and biotechnological manufacturers being inclined toward CDMO services to innovate new products & enter the market, which is expected to contribute to market growth. For instance, in December 2023, AGC declared its plan to enhance its biopharmaceutical CDMO capabilities at the AGC Yokohama Technical Center located in Tsurumi-ku, Yokohama (referred to as the “Yokohama Site” henceforth).
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Recombinant Protein Therapeutics CDMO Market Scope
Recombinant Protein Therapeutics CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Japan recombinant protein therapeutics cdmo market size, by type, 2018-2030 (US$M)
Japan Recombinant Protein Therapeutics CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
